Search

Your search keyword '"Talha Badar"' showing total 5 results
Start Over Author "Talha Badar" Journal leukemia research
5 results on '"Talha Badar"'

2. Comparison between GATA2 and DDX41-mutated myeloid neoplasms

Author

Ahmad Nanaa, Rong He, David Viswanatha, Phuong Nguyen, Dragan Jevremovic, James M. Foran, Cecelia Arana Yi, Patricia T. Greipp, Naseema Gangat, Mrinal Patnaik, Ayalew Tefferi, Mark R. Litzow, Abhishek A. Mangaonkar, Mithun Vinod Shah, Talha Badar, Hassan B. Alkhateeb, and Aref Al-Kali

Subjects
DEAD-box RNA Helicases, GATA2 Transcription Factor, Cancer Research, Leukemia, Myeloid, Acute, Myeloproliferative Disorders, Oncology, Neoplasms, Humans, Hematology
Published
2022

4. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Author

Koichi Takahashi, Guillermo Garcia-Manero, Tapan M. Kadia, Zach Bohannan, Keyur P. Patel, Monica Cabrero, Elias Jabbour, Farhad Ravandi, Talha Badar, Courtney D. DiNardo, Gautam Borthakur, Raja Luthra, Sherry Pierce, Philip A. Thompson, Hagop M. Kantarjian, Jorge E. Cortes, Marina Konopleva, and Naval Daver

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Kaplan-Meier Estimate, medicine.disease_cause, Article, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Codon, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Mutation, Proportional hazards model, business.industry, Myelodysplastic syndromes, Hazard ratio, Myeloid leukemia, Hematology, Middle Aged, Prognosis, medicine.disease, body regions, Leukemia, Myeloid, Acute, Leukemia, Cell Transformation, Neoplastic, Genes, ras, Treatment Outcome, fms-Like Tyrosine Kinase 3, Tandem Repeat Sequences, Myelodysplastic Syndromes, Fms-Like Tyrosine Kinase 3, Disease Progression, Mutation testing, Female, business, psychological phenomena and processes
Abstract

Background The molecular events that drive the transformation from myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) have yet to be fully characterized. We hypothesized that detection of these mutations at the time of transformation from MDS to AML may lead to poorer outcomes. Methods We analyzed 102 MDS patients who were admitted to our institution between 2004 and 2013, had wild-type (wt) FLT3-ITD and RAS at diagnosis, progressed to AML, and had serial mutation testing at both the MDS and AML stages. Results We detected FLT3-ITD and/or RAS mutations in twenty-seven (26%) patients at the time of transformation to AML. Twenty-two patients (81%) had RAS mutations and five (19%) had FLT3-ITD mutations. The median survival after leukemia transformation in patients who had detectable RAS and/or FLT3-ITD mutations was 2.4 months compared to 7.5 months in patients who retained wt RAS and FLT3-ITD (hazard ratio [HR]: 3.08, 95% confidence interval [CI]: 1.9–5.0, p FLT3-ITD and RAS mutations had independent prognostic significance for poor outcome.

Published
2015

5. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

Author

Hagop M. Kantarjian, Srdan Verstovsek, Jorge E. Cortes, Kate J. Newberry, Elias Jabbour, Gautam Borthakur, Naval Daver, Farhad Ravandi, Sherry Pierce, Talha Badar, and Naveen Pemmaraju

Subjects
Male, Oncology, Antimetabolites, Antineoplastic, Cancer Research, medicine.medical_specialty, Decitabine, Leukemia, Myeloid, Accelerated Phase, Article, Internal medicine, medicine, Humans, In patient, Prospective Studies, Myelofibrosis, Accelerated phase, Myeloproliferative neoplasm, Aged, Aged, 80 and over, business.industry, Remission Induction, food and beverages, Myeloid leukemia, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, Survival Analysis, Surgery, Treatment Outcome, Hypomethylating agent, Primary Myelofibrosis, Azacitidine, Female, Blast Crisis, business, medicine.drug
Abstract

Myeloproliferative neoplasm (MPN) transformed to acute myeloid leukemia (MPN-AML), MPN in accelerated phase (MPN-AP), and high-risk primary myelofibrosis (PMF) are associated with a poor response to therapy and very short survival. Several reports have suggested clinical activity of hypomethylating agents in these patients. We conducted a retrospective study of 21 patients with MPN-AML, 13 with MPN-AP and 11 with DIPSS-plus high-risk PMF treated with decitabine at our institution over the last 7 years and evaluated their clinical outcomes. Six patients (29%) with MPN-AML responded to decitabine (3 CR, 2 CRi, and 1 PR); median response duration was 7 months. The median overall survival (OS) was significantly higher in those who responded (10.5 vs 4 months). Among patients with MPN-AP, 8 patients (62%) benefited; the median response duration was 6.5 months. The median OS was 11.8 months in responders vs 4.7 months in non-responders. Among patients with DIPSS-plus high-risk PMF, 9 (82%) benefited; the median response duration was 9 months. The median OS was 32 months in responders vs 16.3 months in non-responders. Decitabine is a viable therapeutic option for patients with MPN-AML, MP-AP and high-risk PMF. Prospective clinical studies combining decitabine with other clinically active agents are needed to improve overall outcome.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results